The vulnerable patient with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 31, Issue 3, 2016, Pages 382-390

  Schlieper, Georg ^a   Hess, Katharina ^a   Floege, Jürgen ^a   Marx, Nikolaus ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

UREMIC TOXIN;

ARTERIAL STIFFNESS; ARTERY INTIMA; ARTERY MEDIA; BLOOD CLOTTING DISORDER; BLOOD VESSEL WALL; CHRONIC KIDNEY DISEASE; ENDOTHELIUM; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HISTOLOGY; HUMAN; HYPERPLASIA; INFLAMMATION; INTIMAL HYPERPLASIA; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; SUDDEN CARDIAC DEATH; UREMIC COAGULOPATHY; UREMIC THROMBOCYTOPATHY; VULNERABLE POPULATION; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; HEALTH; MORBIDITY; RISK FACTOR; SURVIVAL RATE; TRENDS;

CARDIOVASCULAR DISEASES; GLOBAL HEALTH; HUMANS; MORBIDITY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE;

EID: 84960115991     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv041     Document Type: Review

References (100)

1. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672
2. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
3. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079-1084
4. Silberberg JS, Barre PE, Prichard SS, et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290
5. Taddei S, Nami R, Bruno RM, et al. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail Rev 2011; 16: 615-620
6. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
7. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49: 1428-1434
8. Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 2009; 75: 771-773
9. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009; 4(Suppl 1): S79-S91
10. Alhaj E, Alhaj N, Rahman I, et al. Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail 2013; 19: E40-E45
11. Udelson JE. Heart failure with preserved ejection fraction. Circulation 2011; 124: e540-e543
12. Mentz RJ, Kelly JP, Von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014; 64: 2281-2293
13. Gori M, Senni M, Gupta DK, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 2014; 35: 3442-3451
14. Amann K, Kronenberg G, Gehlen F, et al. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 1998; 13: 1958-1966
15. Kramann R, Erpenbeck J, Schneider RK, et al. Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. J Am Soc Nephrol 2014; 25: 2351-2365
16. Perl J, Chan CT. Timing of sudden death relative to the hemodialysis procedure. Nat Clin Pract Nephrol 2006; 2: 668-669
17. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999; 55: 1553-1559
18. Foley RN, Gilbertson DT, Murray T, et al. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 2011; 365: 1099-1107
19. Charytan DM, Reynolds MR. Do implantable defibrillators help patients with CKD? Am J Kidney Dis 2014; 64: 4-6
20. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-223
21. Leskinen Y, Lehtimaki T, Loimaala A, et al. Carotid atherosclerosis in chronic renal failure-the central role of increased plaque burden. Atherosclerosis 2003; 171: 295-302
22. Yoshida H, Yokoyama K, Yaginuma T, et al. Difference in coronary artery intima and media calcification in autopsied patients with chronic kidney disease. Clin Nephrol 2011; 75: 1-7
23. Nakano T, Ninomiya T, Sumiyoshi S, et al. Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama Study. Kidney Int 2013; 84: 373-380
24. Koleganova N, Piecha G, Ritz E, et al. Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2488-2496
25. Chang FC, Chiang WC, Tsai MH, et al. Angiopoietin-2-induced arterial stiffness in CKD. J Am Soc Nephrol 2014; 25: 1198-1209
26. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558
27. Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191
28. John SG, Owen PJ, Harrison LE, et al. The impact of antihypertensive drug therapy on endotoxemia in elderly patients with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2389-2394
29. Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol 2013; 9: 661-670
30. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47: 1027-1034
31. Ketteler M, Rothe H, Kruger T, et al. Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 2011; 7: 509-516
32. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757
33. Jie KE, Zaikova MA, Bergevoet MW, et al. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1875-1882
34. Kramann R, Kunter U, Brandenburg VM, et al. Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. J Bone Miner Res 2013; 28: 2523-2534
35. Ketteler M, Floege J. Calcification and the usual suspect phosphate: still guilty but there are other guys behind the scenes. Nephrol Dial Transplant 2006; 21: 33-35
36. Krueger T, Westenfeld R, Ketteler M, et al. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int 2009; 76: 18-22
37. O'Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010; 25: 187-191
38. O'Neill WC, Adams AL. Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. Kidney Int 2014; 85: 668-676
39. Schlieper G. Vascular calcification in chronic kidney disease: not all arteries are created equal. Kidney Int 2014; 85: 501-503
40. Gauthier-Bastien A, Ung RV, Lariviere R, et al. Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens 2014; 36: 173-180
41. Alam MU, Kirton JP, Wilkinson FL, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009; 81: 260-268
42. Henley C, Davis J, Miller G, et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313
43. Scialla JJ, Leonard MB, Townsend RR, et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2612-2619
44. Chen NX, O'Neill K, Chen X, et al. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease. Am J Nephrol 2013; 37: 191-198
45. Chen NX, O'Neill KD, Chen X, et al. Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. Am J Nephrol 2011; 34: 211-219
46. Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, et al. Calcification of medial elastic fibers and aortic elasticity. Hypertension 1997; 29: 999-1006
47. Schlieper G, Aretz A, Verberckmoes SC, et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 2010; 21: 689-696
48. Shroff RC, McNair R, Skepper JN, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010; 21: 103-112
49. Kokubo T, Ishikawa N, Uchida H, et al. CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol 2009; 20: 1236-1245
50. Langer S, Kokozidou M, Heiss C, et al. Chronic kidney disease aggravates arteriovenous fistula damage in rats. Kidney Int 2010; 78: 1312-1321
51. Lilitkarntakul P, Dhaun N, Melville V, et al. Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 2011; 216: 217-225
52. Recio-Mayoral A, Banerjee D, Streather C, et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-A cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011; 216: 446-451
53. Lilitkarntakul P, Dhaun N, Melville V, et al. Risk factors for metabolic syndrome independently predict arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal comorbidity. Diabetes Care 2012; 35: 1774-1780
54. Sengstock D, Sands RL, Gillespie BWet al. Dominance of traditional cardiovascular risk factors over renal function in predicting arterial stiffness in subjects with chronic kidney disease. Nephrol Dial Transplant 2010; 25: 853-861
55. Moody WE, Edwards NC, Madhani M, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 2012; 223: 86-94
56. Reese PP, Bloom RD, Feldman HI, et al. Mortality and cardiovascular disease among older live kidney donors. Am J Transplant 2014; 14: 1853-1861
57. Tavakol MM, Vincenti FG, Assadi H, et al. Long-term renal function and cardiovascular disease risk in obese kidney donors. Clin J AmSoc Nephrol 2009; 4: 1230-1238
58. Garg AX, Prasad GV, Thiessen-Philbrook HR, et al. Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation 2008; 86: 399-406
59. Speer T, Rohrer L, Blyszczuk P, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013; 38: 754-768
60. Townsend RR, Wimmer NJ, Chirinos JA, et al. AorticPWVin chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2010; 23: 282-289
61. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45: 494-501
62. Madero M, Peralta C, Katz R, et al. Association of arterial rigidity with incident kidney disease and kidney function decline: the Health ABC study. Clin J Am Soc Nephrol 2013; 8: 424-433
63. Chue CD, Edwards NC, Ferro CJ, et al. Effects of age and chronic kidney disease on regional aortic distensibility: a cardiovascular magnetic resonance study. Int J Cardiol 2013; 168: 4249-4254
64. Kimoto E, Shoji T, Shinohara K, et al. Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol 2006; 17: 2245-2252
65. Matsuda N, Takei T, Fujiu A, et al. Arterial stiffness in patients with nondiabetic chronic kidney disease (CKD). J Atheroscler Thromb 2009; 16: 57-62
66. Shroff RC, Donald AE, Hiorns MPet al. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol 2007; 18: 2996-3003
67. London GM, Marchais SJ, Guerin AP, et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-531
68. Briet M, Boutouyrie P, Laurent S, et al. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 2012; 82: 388-400
69. Briet M, Bozec E, Laurent S, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006; 69: 350-357
70. Upadhyay A, Hwang SJ, Mitchell GF, et al. Arterial stiffness in mild-tomoderate CKD. J Am Soc Nephrol 2009; 20: 2044-2053
71. O'Rourke MF, Nichols WW. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 2005; 45: 652-658
72. Saeki A, Recchia F, Kass DA. Systolic flow augmentation in hearts ejecting into a model of stiff aging vasculature. Influence on myocardial perfusiondemand balance. Circ Res 1995; 76: 132-141
73. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129: 1196-1203
74. Castaldi PA, Rozenberg MC, Stewart JH. The bleeding disorder of uraemia. A qualitative platelet defect. Lancet 1966; 2: 66-69
75. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317-322
76. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-589
77. Linthorst GE, Avis HJ, Levi M. Uremic thrombocytopathy is not about urea. J Am Soc Nephrol 2010; 21: 753-755
78. Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int 2012; 82: 147-157
79. Thijs A, Grooteman MP, Zweegman S, et al. Platelet activation during haemodialysis: comparison of cuprammonium rayon and polysulfone membranes. Blood Purif 2007; 25: 389-394
80. Ple H, Maltais M, Corduan A, et al. Alteration of the platelet transcriptome in chronic kidney disease. Thromb Haemost 2012; 108: 605-615
81. Marques M, Sacristan D, Mateos-Caceres PJ, et al. Different protein expression in normal and dysfunctional platelets from uremic patients. J Nephrol 2010; 23: 90-101
82. Burton JO, Hamali HA, Singh R, et al. Elevated levels of procoagulant plasma microvesicles in dialysis patients. PLoS One 2013; 8: e72663
83. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540
84. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573
85. Undas A, Nycz K, PastuszczakMet al. The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. Blood Coagul Fibrinolysis 2010; 21: 522-527
86. Pawlak K, Tankiewicz J, Mysliwiec M, et al. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment. Blood Coagul Fibrinolysis 2009; 20: 590-594
87. Mezzano D, Tagle R, Pais E, et al. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res 1997; 88: 465-472
88. Cetin O, Bekpinar S, Unlucerci Y, et al. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol 2006; 65: 97-102
89. Kario K, Matsuo T, MatsuoMet al. Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995; 73: 763-767
90. Al-Saady NM, Leatham EW, Gupta S, et al. Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart 1999; 81: 134-140
91. Dubin R, Cushman M, Folsom AR, et al. Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol 2011; 12: 3
92. Rumley A, Lowe GD, Sweetnam PM, et al. Factor VIII, vonWillebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999; 105: 110-116
93. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010; 7: 260-273
94. Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012; 7: 1938-1946
95. Goicoechea M, de Vinuesa SG, Gomez-Campdera F, et al. Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4. Kidney Int Suppl 2008; 111: S67-S70
96. Weiner DE, Tighiouart H, Elsayed EF, et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 2008; 51: 212-223
97. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006
98. Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934-947
99. Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23: 1258-1270
100. Jankowski J, van Der Giet M, Jankowski V, et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003; 112: 256-264